查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2019276

全球药物滥用治疗市场：依治疗类型、应用及地区分類的分析－市场规模、产业趋势、机会分析及2026-2035年预测

Global Substance Abuse Treatment Market: Analysis By Treatment Type, End-use, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

药物滥用治疗市场正经历快速成长，预计到 2025 年市场规模将达到 157.2 亿美元，到 2035 年将达到 394.9 亿美元。这一增长意味着在 2026 年至 2035 年的预测期内，复合年增长率高达 9.65%，凸显了在全球范围内解决药物滥用障碍问题日益严峻和迫切的需求。

推动这一上升趋势的关键因素有很多。不同人群成瘾率的上升显着扩大了患者群体，从而对住院和门诊治疗服务产生了持续的需求。同时，远端医疗平台、数位疗法和数据驱动型护理模式等技术进步正在改变治疗的提供方式，提高治疗的可及性和改善患者的治疗效果。

显着的市场趋势

药物滥用治疗市场经历了重大的结构性转型，从小规模独立服务提供者高度分散的生态系统，转变为由少数大型、有影响力的企业主导的更一体化的结构。这种演变造就了寡占的局面，大规模全通路医疗保健机构和资金雄厚的数位颠覆者对当地的定价、服务模式和临床标准拥有显着的影响力。

塑造这一全新市场动态的主要企业包括Acadia Healthcare和Universal Health Services。这两家公司均透过大规模合资企业和策略扩张倡议推动收入成长。凭藉其广泛的医疗机构网络和规模优势，它们正在优化成本、扩大服务范围并增强在多个地区的竞争力。在非营利领域，Hazelden Betty Ford基金会透过提供高品质、品牌化的医疗服务，在高端医疗领域占据主导地位，吸引了许多寻求全面可靠治疗方案的患者。

同时，像Groups Recover Together这样以创新为驱动的新兴参与企业正在重塑门诊辅助性治疗（MAT）领域。这些机构利用科技驱动的医疗服务和高度扩充性的门诊模式，正在重新定义成瘾治疗的可近性和效率。

主要成长要素

由于用户层迅速扩大，以及可及且及时的治疗服务持续短缺，药物滥用治疗的需求正以前所未有的速度增长。据估计，全球约有3,950万人患有严重的药物滥用障碍，问题的严重性和对有效治疗基础设施的迫切需求令人震惊。儘管人们的意识不断提高，政策制定者也日益重视，但许多地区仍面临着服务能力不足、资金限制和就医障碍等问题，导致人们无法获得所需的治疗。

新机会的趋势

Z世代正带着极为复杂的临床特征进入药物滥用治疗市场。他们常常同时服用多种合成药物，常伴随严重的精神疾病，包括临床忧郁症和急性焦虑症。与前几代人不同，Z世代重视的治疗模式不仅要临床有效，还要具有创伤敏感性、文化敏感性，并能包容多元身分。他们期望的治疗环境能反映社会在医疗保健领域向整体性和个人化转变的趋势，并以技术为驱动，高效便捷，且明确支持LGBTQ+群体。

优化障碍

药物滥用治疗市场扩张面临的最大障碍是合格人员的严重短缺。目前，该产业正面临关键临床专业人员25%的供不应求，其中包括成瘾精神科医生、精神科执业护理师和执照临床社会工作者（LCSW）。这种长期短缺给人员配置模式带来了巨大压力，并对整个营运和财务结构产生了连锁反应。过去三年，由于缺乏熟练的专业人员，临床人员的薪资上涨了约18%，这进一步加剧了预算紧张，并增加了医疗保健服务的成本。

目录

第一章执行摘要：全球药物滥用治疗市场

第二章：报告概述

  • 研究框架
    • 研究目标
    • 市场的定义
    • 市场区隔
  • 调查方法
    • 市场规模估算
    • 定性研究
    • 量化研究
    • 按地区分類的主要调查受访者组成
    • 数据检验
    • 调查的前提

第三章：全球药物滥用治疗市场概览

  • 产业价值链分析
    • 原料（活性药物成分、添加物）
    • 药物研发和製剂（解毒剂、辅助性治疗）
    • 生产（片剂、注射剂、植入）
    • 治疗方案的发展（住院治疗、门诊治疗、行为治疗）
    • 服务提供者（復健中心、医院、诊所）
    • 分销通路（药局、线上平台、向医疗机构供货）
    • 最终使用者（患者、復健中心、医疗保健提供者）
  • 产业展望
    • 全球物质使用疾患流行病学
    • 目前的治疗状态（药物治疗和行为疗法结合）
    • 成瘾治疗的医疗基础设施（康復中心和诊所的可用性）
    • 所采用的治疗方法（住院治疗、门诊治疗或数位化治疗）
    • 公共部门和私营部门在医疗保健服务中的作用。
    • 目前产品线状况（新兴治疗方法和临床开发）
    • 报销方案和保险范围
    • 监理情势和政策趋势
  • PESTLE分析
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场成长及前景
    • 市场收入估算与预测（2020-2035 年）
  • 市场吸引力分析
    • 透过治疗方法
  • 可执行的见解（分析师建议）

第四章：竞争对手仪錶板

  • 市场集中度
  • 企业市场占有率分析
  • 竞争格局分析与基准测试

第五章：全球药物滥用治疗市场分析

  • 市场动态和趋势
    • 成长要素
    • 抑制因子
    • 机会
    • 主要趋势
  • 市场规模及预测（2020-2035）
    • 治疗类型
      • 关键见解
        • 烟草/尼古丁和电子烟
        • 酒精
        • 大麻
        • 合成大麻素
        • 处方药和非处方药
        • 其他的
    • 透过使用
      • 关键见解
        • 医院
        • 诊所
        • 復健中心
        • 其他的
    • 按地区
      • 关键见解
        • 北美洲
          • 我们
          • 加拿大
          • 墨西哥
        • 欧洲
          • 西欧
            • 英国
            • 德国
            • 法国
            • 义大利
            • 西班牙
            • 西欧其他地区
          • 东欧
            • 波兰
            • 俄罗斯
            • 东欧其他地区
        • 亚太地区
          • 中国
          • 印度
          • 日本
          • 韩国、澳洲和纽西兰
          • ASEAN
            • 印尼
            • 马来西亚
            • 泰国
            • 新加坡
            • 其他东协国家
            亚太其他地区
        • 中东和非洲
          • 阿拉伯聯合大公国
          • 沙乌地阿拉伯
          • 南非
          • 其他中东和非洲地区
        • 南美洲
          • 阿根廷
          • 巴西
          • 南美洲其他地区

第六章：北美药物滥用治疗市场分析

第七章：欧洲药物滥用治疗市场分析

第八章：亚太地区药物滥用治疗市场分析

第九章：中东和非洲药物滥用治疗市场分析

第十章：南美药物滥用治疗市场分析

第十一章：公司简介

  • Accord Healthcare
  • Amphastar Pharmaceuticals
  • BioCorRx
  • Cipla
  • Glenmark
  • LFB Group
  • Lupin
  • Mylan Laboratories
  • Opiant Technologies
  • Sanofi Aventis
  • Sanquin.
  • Sun Pharma
  • Teva Pharmaceutical
  • Other Prominent Players

第十二章附录

简介目录
Product Code: AA04261753

The substance abuse treatment market is experiencing rapid expansion, with its value estimated at USD 15.72 billion in 2025 and projected to reach USD 39.49 billion by 2035. This growth reflects a strong compound annual growth rate (CAGR) of 9.65% over the forecast period from 2026 to 2035, underscoring the increasing scale and urgency of addressing substance use disorders worldwide.

Several key factors are driving this upward trajectory. Rising addiction rates across diverse populations have significantly expanded the patient pool, creating sustained demand for both inpatient and outpatient treatment services. At the same time, technological advancements-such as telehealth platforms, digital therapeutics, and data-driven care models-are transforming how treatment is delivered, improving accessibility and patient outcomes.

Noteworthy Market Developments

The substance abuse treatment market has undergone a significant structural transformation, shifting from a highly fragmented ecosystem of small, independent providers to a more consolidated landscape dominated by a handful of large, influential players. This evolution has given rise to an oligopolistic environment, where scaled, omni-channel healthcare organizations and well-capitalized digital disruptors now exert substantial control over regional pricing, service delivery models, and clinical standards.

Among the key players shaping this new market dynamic are Acadia Healthcare and Universal Health Services, both of which are driving top-line growth through large-scale joint ventures and strategic expansion initiatives. Their extensive facility networks and operational scale allow them to optimize costs, expand access, and strengthen their competitive positioning across multiple regions. In the non-profit segment, the Hazelden Betty Ford Foundation has established dominance in the premium tier by offering high-quality, brand-driven care that appeals to patients seeking comprehensive and reputable treatment programs.

At the same time, newer, innovation-driven entrants such as Groups Recover Together are reshaping the outpatient medication-assisted treatment (MAT) space. By leveraging technology-enabled care delivery and scalable outpatient models, these organizations are redefining accessibility and efficiency in addiction treatment.

Core Growth Drivers

The demand for substance abuse treatment is increasing at an unprecedented pace, driven by a rapidly expanding consumer base and a continued lack of accessible, timely care. Across the globe, an estimated 39.5 million individuals are affected by severe drug use disorders, highlighting the vast scale of the issue and the urgent need for effective treatment infrastructure. Despite growing awareness and policy attention, many regions still struggle with insufficient capacity, limited funding, and barriers to access that prevent individuals from receiving the care they need.

Emerging Opportunity Trends

The Gen Z population is entering the substance abuse treatment market with uniquely complex clinical profiles, often marked by high rates of synthetic polysubstance use and severe co-occurring mental health conditions, including clinical depression and acute anxiety disorders. Unlike previous cohorts, this generation places a premium on care models that are not only clinically effective but also trauma-informed, culturally sensitive, and responsive to diverse identities. They expect treatment environments that are tech-enabled, streamlined, and explicitly LGBTQ+ affirming, reflecting broader societal shifts toward inclusivity and personalization in healthcare.

Barriers to Optimization

The most significant barrier to scaling operations in the substance abuse treatment market is the acute shortage of qualified human capital. The industry currently experiences a 25% supply gap in essential clinical roles, including Addiction Psychiatrists, Psychiatric Nurse Practitioners, and Licensed Clinical Social Workers (LCSWs). This persistent deficit has put considerable pressure on staffing models, creating a ripple effect throughout operational and financial structures. Over the past three years, the scarcity of skilled professionals has driven clinical wage inflation up by approximately 18%, further straining budgets and increasing the cost of care delivery.

Detailed Market Segmentation

By Treatment Type, the tobacco, nicotine, and vaping segment emerged as the dominant treatment category in the substance abuse market, capturing a 34.26% share and surpassing traditional substances such as opioids and alcohol. This leadership is largely attributed to growing public health concerns surrounding nicotine addiction and vaping-related lung injuries, which have drawn widespread attention from both healthcare providers and regulators. The surge in awareness, coupled with escalating rates of vaping among adolescents and young adults, has created a substantial demand for structured treatment interventions.

By End Use, hospitals accounted for more than 44% of revenue, establishing themselves as the leading end-use segment. Their prominence is largely driven by their ability to manage high-acuity cases, particularly complex polysubstance overdoses involving substances like xylazine-fentanyl combinations, which have increasingly strained emergency departments. Hospitals are uniquely equipped to provide continuous, round-the-clock care, enabling rapid detoxification, ventilatory support, and the integration of psychiatric services, all of which are critical for stabilizing patients in severe crises.

Segment Breakdown

By Treatment Type

  • Tobacco/Nicotine and Vaping
  • Alcohol
  • Marijuana
  • Synthetic Cannabinoids
  • Prescription and Over-the-counter Medications
  • Others

By End-use

  • Hospitals
  • Clinics
  • Rehabilitation Centers
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • The Asia-Pacific region is emerging as a formidable force in the global market, poised to achieve an industry-leading compound annual growth rate (CAGR) of 9.5%. Historically, the region's growth in this sector was constrained by deep-seated cultural stigmas surrounding mental health, as well as strict, often punitive, governmental policies related to drug use and psychological treatment.
  • However, this landscape is undergoing a rapid transformation. By 2026, the rise of a wealthier middle class across countries such as India and several Southeast Asian nations is providing more disposable income that can be allocated toward healthcare and mental wellness services. This economic shift, combined with vigorous government-led campaigns aimed at reducing mental health stigma, has fueled a surge in demand for professional care.
  • In parallel, the digital revolution is enabling new modes of access and treatment, with localized therapy apps and telehealth platforms gaining popularity. These tools not only address geographic and social barriers but also cater to the tech-savvy younger demographic seeking discreet and convenient mental health support. Together, these economic, social, and technological shifts are positioning Asia-Pacific as a sleeper giant in the mental health and wellness industry.

Leading Market Participants

  • Accord Healthcare
  • Amphastar Pharmaceuticals
  • Apotex
  • BioCorRx
  • Cipla
  • Glenmark
  • INSYS Therapeutics
  • LFB Group
  • Lupin
  • Mylan Laboratories
  • Opiant Technologies
  • Sanofi Aventis
  • Sanquin.
  • Sterinova
  • Sun Pharma
  • Teva Pharmaceutical
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Substance Abuse Treatment Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Substance Abuse Treatment Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Materials (Active Pharmaceutical Ingredients, Excipients)
    • 3.1.2. Drug Development & Formulation (Detox Medications, MAT Therapies)
    • 3.1.3. Manufacturing (Tablets, Injectables, Implants)
    • 3.1.4. Treatment Program Development (Inpatient, Outpatient, Behavioral Therapy)
    • 3.1.5. Service Providers (Rehabilitation Centers, Hospitals, Clinics)
    • 3.1.6. Distribution Channels (Pharmacies, Online Platforms, Institutional Supply)
    • 3.1.7. End User (Patients, Rehab Centers, Healthcare Providers)
  • 3.2. Industry Outlook
    • 3.2.1. Global Epidemiology of Substance Use Disorders
    • 3.2.2. Treatment Landscape (Pharmacological vs Behavioral Therapy Mix)
    • 3.2.3. Healthcare Infrastructure for Addiction Treatment (Rehab Centers, Clinics Availability)
    • 3.2.4. Adoption of Treatment Modalities (Inpatient vs Outpatient vs Digital Care)
    • 3.2.5. Role of Public vs Private Sector in Treatment Delivery
    • 3.2.6. Pipeline Landscape (Emerging Therapies & Clinical Developments)
    • 3.2.7. Reimbursement Scenario & Insurance Coverage
    • 3.2.8. Regulatory & Policy Landscape
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Treatment Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Substance Abuse Treatment Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
      • 5.1.1.1. Rising Global Prevalence of Substance Use Disorders (SUDs) with a Large Untreated Population
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Treatment Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Tobacco/Nicotine and Vaping
        • 5.2.1.1.2. Alcohol
        • 5.2.1.1.3. Marijuana
        • 5.2.1.1.4. Synthetic Cannabinoids
        • 5.2.1.1.5. Prescription and Over-the-counter Medications
        • 5.2.1.1.6. Others
    • 5.2.2. By End-Use
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Hospitals
        • 5.2.2.1.2. Clinics
        • 5.2.2.1.3. Rehabilitation Centers
        • 5.2.2.1.4. Others
    • 5.2.3. By Region
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. North America
          • 5.2.3.1.1.1. The U.S.
          • 5.2.3.1.1.2. Canada
          • 5.2.3.1.1.3. Mexico
        • 5.2.3.1.2. Europe
          • 5.2.3.1.2.1. Western Europe
            • 5.2.3.1.2.1.1. The UK
            • 5.2.3.1.2.1.2. Germany
            • 5.2.3.1.2.1.3. France
            • 5.2.3.1.2.1.4. Italy
            • 5.2.3.1.2.1.5. Spain
            • 5.2.3.1.2.1.6. Rest of Western Europe
          • 5.2.3.1.2.2. Eastern Europe
            • 5.2.3.1.2.2.1. Poland
            • 5.2.3.1.2.2.2. Russia
            • 5.2.3.1.2.2.3. Rest of Eastern Europe
        • 5.2.3.1.3. Asia Pacific
          • 5.2.3.1.3.1. China
          • 5.2.3.1.3.2. India
          • 5.2.3.1.3.3. Japan
          • 5.2.3.1.3.4. South Korea
          • 5.2.3.1.3.5. Australia & New Zealand
          • 5.2.3.1.3.6. ASEAN
            • 5.2.3.1.3.6.1. Indonesia
            • 5.2.3.1.3.6.2. Malaysia
            • 5.2.3.1.3.6.3. Thailand
            • 5.2.3.1.3.6.4. Singapore
            • 5.2.3.1.3.6.5. Rest of ASEAN
          • 5.2.3.1.3.7. Rest of Asia Pacific
        • 5.2.3.1.4. Middle East & Africa
          • 5.2.3.1.4.1. UAE
          • 5.2.3.1.4.2. Saudi Arabia
          • 5.2.3.1.4.3. South Africa
          • 5.2.3.1.4.4. Rest of MEA
        • 5.2.3.1.5. South America
          • 5.2.3.1.5.1. Argentina
          • 5.2.3.1.5.2. Brazil
          • 5.2.3.1.5.3. Rest of South America

Chapter 6. North America Substance Abuse Treatment Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Treatment Type
    • 6.2.2. By End-Use
    • 6.2.3. By Country

Chapter 7. Europe Substance Abuse Treatment Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Treatment Type
    • 7.2.2. By End-Use
    • 7.2.3. By Country

Chapter 8. Asia Pacific Substance Abuse Treatment Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Treatment Type
    • 8.2.2. By End-Use
    • 8.2.3. By Country

Chapter 9. Middle East & Africa Substance Abuse Treatment Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Treatment Type
    • 9.2.2. By End-Use
    • 9.2.3. By Country

Chapter 10. South America Substance Abuse Treatment Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Treatment Type
    • 10.2.2. By End-Use
    • 10.2.3. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. Accord Healthcare
  • 11.2. Amphastar Pharmaceuticals
  • 11.3. BioCorRx
  • 11.4. Cipla
  • 11.5. Glenmark
  • 11.6. LFB Group
  • 11.7. Lupin
  • 11.8. Mylan Laboratories
  • 11.9. Opiant Technologies
  • 11.10. Sanofi Aventis
  • 11.11. Sanquin.
  • 11.12. Sun Pharma
  • 11.13. Teva Pharmaceutical
  • 11.14. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators